Orange Book product · Brand (NDA)
YCANTH
CANTHARIDIN
At a glance
Jul 21, 2023
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 21, 2023
2 yr 11 mo ago
Today
Exclusivity ends · NCE
New chemical entity exclusivity (5 years)
Jul 21, 2028
in 2 yr 1 mo
Patent 11052064 expires
Listed drug product patent expiration.
May 28, 2035
in 9 yr 1 mo
Patent 11052064 expires
Listed drug product patent expiration.
May 28, 2035
in 9 yr 1 mo
Patent 11147790 expires
Listed drug product patent expiration.
Aug 22, 2038
in 12 yr 4 mo
Patent 11147790 expires
Listed drug product patent expiration.
Aug 22, 2038
in 12 yr 4 mo
Patent 12233042 expires
Listed drug product patent expiration.
Aug 22, 2038
in 12 yr 4 mo
Patent 12290651 expires
Listed drug product patent expiration.
Feb 19, 2041
in 14 yr 11 mo
Pharmaceutical detail
Active ingredient
CANTHARIDIN
Strength
0.7%
Dosage form
SOLUTION
Route
TOPICAL
TE code
Not listed
Application
NDA 212905
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Marketing exclusivity (1)
- NCENew chemical entity exclusivity (5 years)
Jul 21, 2028
in 2 yr 1 mo
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11052064 | May 28, 2035 | in 9 yr 1 mo | ProductU-3665 |
| 11052064 | May 28, 2035 | in 9 yr 1 mo | ProductU-3663 |
| 11147790 | Aug 22, 2038 | in 12 yr 4 mo | ProductU-3663 |
| 11147790 | Aug 22, 2038 | in 12 yr 4 mo | ProductU-3664 |
| 12233042 | Aug 22, 2038 | in 12 yr 4 mo | ProductU-3663 |
| 12290651 | Feb 19, 2041 | in 14 yr 11 mo | Product |
